Compugen Ltd., the Israeli drug developer, said that it has created a new panel to advise the company as it develops treatments in the immunology and oncology fields.
The company’s newly created scientific advisory board has four members. They are: Charles Drake, an associate professor of oncology, immunology and urology at Johns Hopkins Kimmel Cancer Center; Iain McInnes, director of the University of Glasgow’s Institute of Infection, Immunity, and Inflammation; Antoni Ribas, professor at the University of California Los Angeles’ department of medicine, hematology and oncology; and Howard Soule, executive vice president of the Prostate Cancer Foundation.
Shares of Compugen rose 59 cents, or 6 percent, to close at $10.57 Monday, after hitting a 52-week high of $10.60 earlier.
Date: August 26, 2013
Source: Associated Press
